Genetic clues to severe preeclampsia could transform early detection

NCT ID NCT07703826

Not yet recruiting Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study investigates genetic and molecular markers in pregnant women with severe preeclampsia, a dangerous condition involving high blood pressure and organ damage. Researchers will analyze blood, urine, and placental samples from 100 women to identify changes in genes and cell types that distinguish severe cases from healthy pregnancies. The goal is to improve early screening and understand the biological roots of the condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could identify early screening markers for severe preeclampsia and uncover its underlying causes.
What could go wrong: This is an observational study with a small sample size (100 participants), so findings may not apply broadly and require further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

preeclampsia severe pre-eclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREECLAMPSIA SEVERE PREECLAMPSIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.